Navigation Links
Study Finds Long-Term Treatment with TRIBENZOR™ was Effective and Well-Tolerated Regardless of Age, Race, or Diabetes Status
Date:5/23/2011

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Data evaluating the long-term efficacy and safety of olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide (OM/AML + HCTZ) in patients with hypertension aged <65 years and greater than or equal to 65 years, showed that the triple therapy at Week 52 was both well-tolerated and effective in maintaining the blood pressure reductions seen in the pivotal study regardless of age.(1)

The pre-specified subgroup analysis results, presented for the first time at the American Society of Hypertension, Inc. (ASH) Twenty-Sixth Annual Scientific Meeting and Exposition (ASH 2011) in New York, found that a similar percentage of patients treated with the triple therapy achieved BP goal in both age groups. The triple therapy was well-tolerated in both age groups and most adverse events (AE) were mild or moderate in severity.(1)

"Older patients generally have a more difficult time achieving recommended blood pressure levels and as a result, their hypertension often remains uncontrolled," said Suzanne Oparil, MD, Professor of Medicine and Physiology and Biophysics at the University of Alabama School of Medicine. "However this analysis shows that long-term blood pressure control can be achieved safely and effectively across all studied dosing strengths with a triple combination therapy regardless of age. This is important given the fact that more than 64 percent of men and 75 percent of women 70 years or older have high blood pressure."(5)

The long-term open-label extension of the TRINITY study (Triple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hypertensive Patients Study) evaluated the safety and efficacy of olmesartan medoxomil (OM)/amlodipine (AML) + hydrochlorothiazide (HCTZ) in 2,098 patients with hypertension.(1) After completing a 12-week double-blind period, eligible patients were enrolled
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... NEW YORK and KISSING, Germany ... manufacturer and distributor of a single use and computer-assisted ... Nachum (Homi) Shamir , a worldwide recognized medical device ... Mr. Shamir is a highly respected ... most recent assignment he served as President and Chief ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: ... into the cannabis testing and education markets, announced today ... and affairs not previously disclosed or, to its knowledge, ... market action. "We have noticed unusual price ... three trading days," said Steve Barbee , CEO ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , SAN FRANCISCO, Nov. 4 VIA Pharmaceuticals, Inc. ... the development of compounds for the treatment of cardiovascular ... Senior Vice President Research & Development will present "VIA-3196, ... in the Abstract Oral Session on Novel Biological Mechanisms ...
... CVS Caremark (NYSE: CVS ) today announced ... SVP, Marketing for its pharmacy benefit management business. ... Jack Bruner, who is transitioning to the new role ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings twenty years ...
Cached Medicine Technology:VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 2VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 3VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 4Company Appoints New SVP, Marketing for PBM Business 2
(Date:7/30/2014)... San Francisco, California (PRWEB) July 30, 2014 ... reach USD 46.05 billion by 2020, according to a ... for minimally invasive procedures and the growing prevalence of ... market growth over the forecast period. In addition, the ... the rising market penetration of minimally invasive procedures in ...
(Date:7/30/2014)... Building ENT and Allergy Associates (ENTA) into ... in Westchester County takes the best of everything. Leading ... corporate structure and protocols, and a staff that is ... Chief Financial Officer to help run it. According to ... it possesses. In fact, in the WCBJ’s July 21st, ...
(Date:7/30/2014)... 30, 2014 All the children at ... abandonment, rejection, abuse and exploitation tend to mar their ... hopelessness and dejection. Quality youth development has underpinnings in ... support boosts confidence and in the foreseeable future, would ... this light that the mere presence of Foundation members ...
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July 29, ... set the stage for harmful health habits, including eating disorders, ... from 1982 to 2012 also found a link between early ... a woman was when she started her first diet, the ... behaviors -- like vomiting or laxative misuse," said study researcher ...
(Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... nutrients in fruits and vegetables are vital to good health ... Once you,ve hit five servings of fruits and vegetables each ... new research review suggests. The human body may only ... and vegetables every day, limiting its ability to absorb important ...
Breaking Medicine News(10 mins):Health News:Global Catheters Market - Industry Size, Trends, Analysis, Growth, Players, Outlook and Forecast Research Report from 2014 to 2020: Grand View Research, Inc 2Health News:Global Catheters Market - Industry Size, Trends, Analysis, Growth, Players, Outlook and Forecast Research Report from 2014 to 2020: Grand View Research, Inc 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3Health News:The Edusei Foundation Donates Food and Assorted Items to the Fathers’ Home Care Ministries in Takoradi, Ghana 2Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 2Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 3
... at the 5th Annual Games for Health Conference ... Project, organizers of the 5th Annual Games for Health ... by SharpBrains, a leading market research company focused on ... Cognitive Health track builds upon previous year,s sampling of ...
... benefit Christopher & Dana Reeve FoundationSHORT HILLS, N.J., May ... will be held Monday, June 22nd at 8:00 ... New York. Directed by Marcia Milgrom Dodge, currently directing ... Larry Yurman ("Grey Gardens"), Born for Broadway ...
... experts say consequence can be severe , , MONDAY, May 18 ... the health-care industry as it tries to serve the poor, ... 10 poor women recovering from breast cancer do not ... , Those who do not follow instructions to take these ...
... LEHIGH VALLEY, Pa., May 18 Air Products (NYSE: ... three of its U.S. healthcare businesses to Landauer-Metropolitan, Inc. ... and infusion services in the northeast, based in Mount ... disclosed.The sale includes Air Products, ownership interests in certain ...
... Associate,s Degrees to Earn Their Master,s SALT LAKE CITY, May ... www.wgu.edu , has launched two new master,s degree programs ... the RN to MSN in Nursing Leadership and Management. The ... registered nurses who have an associate,s degree or diploma in ...
... education come fewer chronic problems, study finds , , MONDAY, May ... appear to have a better chance of living a longer ... Social Research Council, who analyzed data from 2002 to 2007, ... were richer and better educated were less likely to have ...
Cached Medicine News:Health News:Games for Health Conference Announces First Cognitive Health Track Powered by SharpBrains 2Health News:Games for Health Conference Announces First Cognitive Health Track Powered by SharpBrains 3Health News:Games for Health Conference Announces First Cognitive Health Track Powered by SharpBrains 4Health News:Tickets Now on Sale for Born for Broadway 2Health News:Poor Women Seem to Be Skipping Breast Cancer Drugs 2Health News:Air Products Sells Three U.S. Healthcare Businesses to Landauer-Metropolitan 2Health News:Western Governors University Offers Two New Master's Degrees in Nursing 2Health News:Western Governors University Offers Two New Master's Degrees in Nursing 3Health News:Money May Matter, Health-Wise, in Old Age 2
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... Pipettor is the #1 Pipettor for ... comfort, and reliability. Continuously adjustable. Features ... sub-micrometer. Easy interchangeable ejector buttons to ... Adjustable rapid pipet tip ejector with ...
... Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic ... greasing. Volume Range(ul) ... 0.8~1.5 Imprecision(%) ... Precision (ul) ...
Medicine Products: